IGC PHARMA INC (IGC) Stock News

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

IGC Pharma Reports Third Quarter Fiscal 2025 Results

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease

The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Announces Results of its 2024 Annual Stockholders Meeting

InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025

IGC stock results show that IGC Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!

Mentions: VLCN SNTI GLYC LEAS ...

IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024

IGC stock results show that IGC Pharma met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2024.

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets